Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

About Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: SRPT
CUSIP:

Key Metrics:

Previous Close: $57.83
50 Day Moving Average: $30.90
200 Day Moving Average: $22.21
52-Week Range: $47,899,000.00 - $8.00
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -25.59
P/E Growth: 69.35
Market Cap: $2.77B
Outstanding Shares: 47,899,000
Beta: 1.61

Profitability:

Return on Equity: -157.82%
Return on Assets: -106.30%

Debt:

Debt-to-Equity Ratio: 0.10%
Current Ratio: 2.91%
Quick Ratio: 2.91%

Additional Links:

Companies Related to Sarepta Therapeutics:

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)

Ratings Breakdown:	1 Sell Rating, 3 Hold Ratings, 13 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:	Buy (Score: 2.78)
Consensus Price Target:	$51.76 (10.49% downside)

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:SRPT)

Show:

Date	Firm	Action	Rating	Price Target
9/20/2016	WBB Securities	Reiterated Rating	Strong-Buy	$40.00 -> $60.00
9/20/2016	Needham & Company LLC	Boost Price Target	Buy	$47.00 -> $81.00
9/20/2016	Wedbush	Reiterated Rating	Outperform	$66.00
9/20/2016	Cowen and Company	Upgrade	Market Perform -> Outperform	$64.00
9/19/2016	Oppenheimer Holdings Inc.	Boost Price Target		$60.00 -> $76.00
9/19/2016	JMP Securities	Upgrade	Outperform	$10.00 -> $60.00
9/19/2016	Jefferies Group	Upgrade	Underperform -> Hold	$50.00
9/19/2016	RBC Capital Markets	Upgrade	Sector Perform -> Outperform
9/19/2016	Leerink Swann	Upgrade	Underperform -> Market Perform	$50.00
9/19/2016	Royal Bank Of Canada	Upgrade	Sector Perform -> Outperform	$83.00
9/19/2016	Piper Jaffray Cos.	Upgrade	Neutral -> Overweight
9/19/2016	William Blair	Upgrade	Market Perform -> Outperform	$88.00
9/19/2016	Janney Montgomery Scott	Upgrade	Neutral -> Buy	$30.00 -> $65.00
9/14/2016	SunTrust Banks Inc.	Upgrade	Reduce -> Neutral
7/18/2016	Robert W. Baird	Reiterated Rating	Outperform	$23.00
5/5/2016	Ladenburg Thalmann	Downgrade	Market Perform -> Underperform	$13.00 -> $5.00
11/8/2015	Roth Capital	Reiterated Rating	Buy	$50.00
10/23/2015	Bank of America Corp.	Initiated Coverage	Buy	$49.00
9/1/2015	Susquehanna	Boost Price Target	Neutral	$33.00 -> $36.00
5/23/2015	Deutsche Bank AG	Reiterated Rating	Hold	$24.00
5/20/2015	Canaccord Genuity	Upgrade	Hold -> Buy	$16.00 -> $30.00
1/27/2015	Northland Securities	Upgrade	Market Perform -> Outperform	$3.00
10/27/2014	Stifel Nicolaus	Downgrade	Buy -> Hold
10/7/2014	Credit Suisse Group AG	Reiterated Rating	Outperform

(Data available from 9/26/2014 forward)

Earnings History for Sarepta Therapeutics (NASDAQ:SRPT)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/3/2016
7/19/2016	Q2	($1.19)	($1.35)			View	N/A
5/5/2016	Q1	($1.30)	($1.15)	$0.18 million		View	N/A
2/24/2016	Q4	($1.18)	($1.30)		$1.25 million	View	N/A
11/5/2015	Q315	($1.19)	($1.25)			View	Listen
8/6/2015	Q215	($1.21)	($1.01)	$0.31 million	$0.01 million	View	Listen
5/7/2015	Q115	($1.00)	($1.49)	$0.78 million		View	Listen
2/26/2015	Q414	($0.82)	($0.94)	$1.56 million	$0.30 million	View	Listen
11/6/2014	Q314	($0.96)	($0.70)	$3.07 million	$1.10 million	View	Listen
8/7/2014	Q214	($0.76)	($0.85)	$4.30 million	$2.58 million	View	Listen
5/8/2014	Q114	($0.80)	($0.75)	$3.45 million	$6.09 million	View	Listen
2/27/2014	Q413	($0.69)	($0.77)	$4.53 million	$2.60 million	View	Listen
11/12/2013	Q313	($0.65)	($0.63)	$4.57 million	$4.20 million	View	Listen
8/8/2013	Q2 2013	($0.67)	($0.46)	$5.08 million	$3.00 million	View	Listen
5/9/2013	Q1 2013	($0.62)	($0.41)	$5.85 million	$4.50 million	View	Listen
3/7/2013	Q4 2012	($0.26)	($2.36)	$6.71 million	$7.30 million	View	Listen
11/7/2012		($0.27)	($2.17)	$10.06 million	$7.57 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Current Year EPS Consensus Estimate: $-5.14 EPS
Next Year EPS Consensus Estimate: $-2.26 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	4	($1.40)	($1.17)	($1.29)
Q2 2016	5	($1.32)	($0.62)	($1.08)
Q3 2016	6	($1.38)	($0.59)	($1.09)
Q4 2016	6	($1.22)	($0.47)	($0.86)
Q1 2017	1	($0.80)	($0.80)	($0.80)
Q2 2017	1	($0.85)	($0.85)	($0.85)
Q3 2017	1	($0.78)	($0.78)	($0.78)
Q4 2017	1	($0.84)	($0.84)	($0.84)

(Data provided by Zacks Investment Research)

Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Sarepta Therapeutics (NASDAQ:SRPT)

Insider Ownership Percentage: 10.90%
Institutional Ownership Percentage: 72.09%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/19/2016	David T Howton	SVP	Sell	9,304	$50.00	$465,200.00
9/19/2016	Edward M Md Kaye	CEO	Sell	24,352	$50.00	$1,217,600.00
9/19/2016	Jayant Aphale	VP	Sell	35,000	$50.00	$1,750,000.00
9/14/2016	Edward M Md Kaye	CEO	Sell	24,557	$30.00	$736,710.00
3/16/2016	M Kathleen Behrens	Director	Buy	10,000	$14.54	$145,400.00
3/14/2016	M Kathleen Behrens	Director	Buy	65,000	$16.54	$1,075,100.00
11/14/2013	Anthony Chase	Director	Buy	10,000	$13.95	$139,500.00
9/16/2013	M Kathleen Behrens	Director	Buy	6,500	$37.04	$240,760.00
9/3/2013	John Hodgman	Director	Sell	5,556	$34.97	$194,293.32
8/22/2013	Anthony Chase	Director	Buy	3,500	$32.68	$114,380.00
8/20/2013	Sandesh Mahatme	CFO	Buy	5,000	$31.10	$155,500.00
6/14/2013	Anthony R Chase	Director	Buy	10,000	$38.50	$385,000.00
9/7/2012	M Kathleen Behrens	Director	Buy	17,500	$14.73	$257,775.00

(Data available from 1/1/2013 forward)

Latest Headlines for Sarepta Therapeutics (NASDAQ:SRPT)

Date	Headline
	For Traders, Planning Is More Important Than the Plan (NASDAQ:SRPT) realmoney.thestreet.com - September 25 at 11:58 AM
	The Woman Behind Sarepta Therapeutics' Success (NASDAQ:SRPT) www.fool.com - September 24 at 8:31 AM
	Sarepta Therapeutics : Group One Trading buys $14,427,123 stake in Sarepta Therapeutics Inc (SRPT) (NASDAQ:SRPT) www.4-traders.com - September 23 at 6:51 PM
	SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St (NASDAQ:SRPT) biz.yahoo.com - September 23 at 6:51 PM
	Sarepta: Look For Lift Post Impressive Secondary Price (NASDAQ:SRPT) seekingalpha.com - September 23 at 11:29 AM
	Sizzling Sarepta Therapeutics Inc (SRPT) Targeted by Option Bulls (NASDAQ:SRPT) www.schaeffersresearch.com - September 23 at 11:29 AM
	Company Update (NASDAQ:SRPT): Sarepta Therapeutics Inc Announces Pricing of $300 Million Public Offering of Common Stock (NASDAQ:SRPT) www.smarteranalyst.com - September 23 at 11:29 AM
	2:40 am Sarepta Therapeutics prices 5.02 mln shares of its common stock at $59.75 per share (NASDAQ:SRPT) finance.yahoo.com - September 23 at 11:29 AM
	Sizzling Sarepta Therapeutics Inc (SRPT) Targeted by Option Bulls - Schaeffers Research (blog) (NASDAQ:SRPT) www.schaeffersresearch.com - September 22 at 7:06 PM
	Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock (NASDAQ:SRPT) www.publicnow.com - September 22 at 7:06 PM
	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Trading Up – Insider Trading Activity (NASDAQ:SRPT) www.fidaily.com - September 22 at 11:37 AM
	Sarepta Therapeutics Inc (SRPT) Shares Rise Amid $225 Million Stock Offering (NASDAQ:SRPT) www.thecountrycaller.com - September 22 at 11:37 AM
	How Sarepta Is Cashing In on Its FDA Homerun (NASDAQ:SRPT) 247wallst.com - September 22 at 11:37 AM
	I Am One of the Underinvested Bulls Right Now (NASDAQ:SRPT) realmoney.thestreet.com - September 22 at 11:37 AM
	Sarepta to Sell Up to $225 Million of Stock (NASDAQ:SRPT) ih.advfn.com - September 21 at 6:59 PM
	William Blair Weighs in on Sarepta Therapeutics Inc (SRPT) Following Favorable Decision in Patent Appeal (NASDAQ:SRPT) www.smarteranalyst.com - September 21 at 6:59 PM
	Sarepta Therapeutics Announces Proposed Public Offering of Common Stock (NASDAQ:SRPT) finance.yahoo.com - September 21 at 6:59 PM
	[$$] Sarepta to Sell Up to $225 Million of Stock (NASDAQ:SRPT) www.wsj.com - September 21 at 6:59 PM
	BRIEF-Sarepta Therapeutics announces offering to sell up to $225 mln of stock (NASDAQ:SRPT) feeds.reuters.com - September 21 at 4:58 PM
	Sarepta Therapeutics (SRPT) Appoints Edward Kaye as Permanent CEO; Updates on Exec Team - StreetInsider.com (NASDAQ:SRPT) www.streetinsider.com - September 21 at 11:34 AM
	Company Update (NASDAQ:SRPT): Sarepta Therapeutics Inc ... - Smarter Analyst (NASDAQ:SRPT) www.smarteranalyst.com - September 21 at 11:34 AM
	Analysts Dive in on Two Volatile Biotech Stocks: Sarepta Therapeutics Inc (SRPT), Vical Incorporated (VICL) - Smarter Analyst (NASDAQ:SRPT) www.smarteranalyst.com - September 21 at 11:34 AM
	Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy (NASDAQ:SRPT) www.fool.com - September 20 at 4:19 PM
	Here's Why Sarepta Therapeutics, Inc's Stock is Jumping Again (NASDAQ:SRPT) www.fool.com - September 20 at 1:13 PM
	Sarepta Therapeutics Inc (NASDAQ:SRPT) & Finisar Corporation (NASDAQ:FNSR) UPDATE ON U.S STOCKS : 19 ... - Money News (NASDAQ:SRPT) www.newsismoney.com - September 20 at 11:12 AM
	Analyst Upgrades: Sarepta Therapeutics Inc, Cirrus Logic, Inc., and Advanced Micro Devices, Inc. - Schaeffers Research (blog) (NASDAQ:SRPT) www.schaeffersresearch.com - September 20 at 11:12 AM
	Puma Biotechnology: Sarepta Isn't the Only Biotech Getting a Boost From the FDA (NASDAQ:SRPT) blogs.barrons.com - September 20 at 11:12 AM
	Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug (NASDAQ:SRPT) finance.yahoo.com - September 20 at 11:12 AM
	Company News for September 20, 2016 (NASDAQ:SRPT) finance.yahoo.com - September 20 at 11:12 AM
	Sarepta Muscular Dystrophy Drug Will Cost $300K; Acquisition Target? (NASDAQ:SRPT) www.investors.com - September 20 at 11:12 AM
	The Market In 5 Minutes: Traders In A Standstill Ahead Of FOMC Meeting (NASDAQ:SRPT) feeds.benzinga.com - September 20 at 9:24 AM
	Sarepta Therapeutics Inc (NASDAQ:SRPT): Our Subecribers Bought The Stock At $28 And Now Up 85% Quickly (NASDAQ:SRPT) www.marketnewscall.com - September 19 at 7:23 PM
	Here’s Why Sarepta Therapeutics Inc Is Up 80% Today (SRPT) (NASDAQ:SRPT) investorplace.com - September 19 at 7:23 PM
	Notable Analyst Price Target Changes: Sarepta Therapeutics Inc (SRPT), GoPro Inc (GPRO) (NASDAQ:SRPT) www.smarteranalyst.com - September 19 at 7:23 PM
	Cramer Remix: Another speculative biotech with tremendous upside (NASDAQ:SRPT) www.cnbc.com - September 19 at 7:23 PM
	Why Infoblox Inc (BLOX), Isle of Capri Casinos (ISLE) and Sarepta Therapeutics Inc (SRPT) Are 3 of Today’s Best Stocks (NASDAQ:SRPT) investorplace.com - September 19 at 5:31 PM
	Mid-Day Market Update: Crude Oil Up 2%; Sarepta Therapeutics Shares Spike Higher (NASDAQ:SRPT) feeds.benzinga.com - September 19 at 12:47 PM
	Most Active Weekly Options: Sarepta Therapeutics Inc and Chesapeake Energy Corporation - Schaeffers Research (blog) (NASDAQ:SRPT) www.schaeffersresearch.com - September 19 at 11:58 AM
	FDA Approves Sarepta Therapeutics' (SRPT) Eteplirsen - StreetInsider.com (NASDAQ:SRPT) www.streetinsider.com - September 19 at 11:58 AM
	Sarepta Stock Soars On FDA OK For Muscular Dystrophy Drug (NASDAQ:SRPT) www.investors.com - September 19 at 11:58 AM
	Sarepta Wins FDA Nod For Embattled DMD Drug -- But With A Catch (NASDAQ:SRPT) www.forbes.com - September 19 at 11:58 AM
	FDA grants accelerated approval to Sarepta’s Duchenne drug (NASDAQ:SRPT) www.bizjournals.com - September 19 at 11:58 AM
	Sarepta Therapeutics Inc (SRPT), PTC Therapeutics, Inc. (PTCT) and More: Here’s Why These Stocks Are on Investors’ Radars Today (NASDAQ:SRPT) www.insidermonkey.com - September 19 at 11:58 AM
	[$$] FDA Approves Sarepta's Dystrophy Drug (NASDAQ:SRPT) www.wsj.com - September 19 at 11:58 AM
	Here’s Why Sarepta Therapeutics Inc Is Up 80% Today (SRPT) (NASDAQ:SRPT) investorplace.com - September 19 at 11:40 AM
	Sarepta shares briefly leap 80% after FDA approves drug (NASDAQ:SRPT) www.cnbc.com - September 19 at 11:00 AM
	BRIEF-U.S. FDA grants accelerated approval to Sarepta Therapeutics' Duchenne Muscular Dystrophy drug (NASDAQ:SRPT) feeds.reuters.com - September 19 at 10:39 AM
	Sarepta Therapeutics Inc (NASDAQ:SRPT): Jefferies Says Chances for Eteplirsen’s Approval Are Still Slim (NASDAQ:SRPT) www.bidnessetc.com - September 18 at 11:36 AM
	Bank of America Corp (NYSE:BAC) & Sarepta Therapeutics Inc ... - Money News (NASDAQ:SRPT) www.newsismoney.com - September 16 at 7:08 PM
	Biotech Stocks Worth a Closer Look: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), Sarepta Therapeutics, Inc ... - The Voice Registrar (NASDAQ:SRPT) voiceregistrar.com - September 16 at 7:08 PM